John L. Lamattina

Drug Truths (eBook, PDF)

Dispelling the Myths About Pharma R & D

• Format: PDF

Produktbeschreibung

This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Development, weaves themes critical to a vital drug discovery environment in the context. This is a story that Dr. LaMattina is uniquely qualified to tell.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: John Wiley & Sons
• Seitenzahl: 152
• Erscheinungstermin: 12. November 2008
• Englisch
• ISBN-13: 9780470434659
• Artikelnr.: 37292267

Autorenporträt

John L. LaMattina, PhD, retired as president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire.

Inhaltsangabe

Acknowledgments. Introduction. PART 1: A MATTER OF THE HEART. Chapter 1:
Cholesterol Drugs Are Unnecessary. Chapter 2: Industry is More Interested
in "Me-Too" Drugs Than in Innovation. Chapter 3: It Takes Industry Too Long
to Discover New Drugs. PART 2: THE ROLE OF PHARMACEUTICAL R&D IN
HEALTHCARE. Chapter 4: Drugs Are Discovered by Academia. Chapter 5: New
Medicines Add Costs but Little Benefit. Chapter 6: Big Pharma Has Failed
and Should Learn From Biotech Success. PART 3: THE PROFIT MOTIVE. Chapter
7: The Industry Invents Diseases. Chapter 8: New Drugs Are Less Safe Than
Traditional Medicines. Chapter 9: Industry Spends More on Advertising Than
R&D. Chapter 10: Industry Does Not Care About Diseases of the Developing
World. PART 4: THE FUTURE. Chapter 11: Big Pharma's Day Has Passed. Chapter
12: Final Reflections. References. Index.